Immunotherapy in Solid Tumors

Dear Colleagues,

Immunotherapy has emerged as a major therapeutic modality in oncology. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. These therapeutics help the host immune system recognize cancer as foreign, promote the immune system, and relieve the inhibition that allows growth and spread of tumors. 

Despite the advancements in the treatment of hematological malignancies, solid tumors still represent a challenge. The majority of patients with cancer do not derive benefit from these treatments. Vascular abnormalities are a hallmark of most solid tumors and facilitate immune evasion. These underscore the importance of understanding basic tumor immunology for successful clinical translation in treating patients with cancer. 

The recent clinical successes of immune checkpoint blockade therapies represent a turning point in immunotherapy. In addition, other immunotherapeutic treatments, such as vaccines, antibody-based targeted therapies, and adoptive therapies, are being investigated to treat solid tumors.

This Special Issue intends to present insights into the novel approaches in immunotherapy and discuss existing and emerging immunotherapy technologies that hope to translate the promise of immunotherapy for the treatment of solid tumors into clinical reality.

Dr. Gaia Zuccolotto
Dr. Giulio Fracasso
Dr. Debora Carpanese
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• immunotherapy
• solid Tumors
• targeted therapies
• adoptive therapies
• basic tumor immunology